ClinicalTrials.gg
WithdrawnNCT06570434Updated Oct 16, 2024

Phase 1b/2a in SLE With Budoputug

A Phase 1/2 interventional study of budoprutug in Systemic Lupus Erythematosus, SLE and B Cells, sponsored by Tenet Medicines. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Tenet Medicines · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Study was never initiated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of budoprutug in participants with SLE

Read the detailed description

This is a Phase 1b/2a, multicenter, open-label study designed to evaluate the safety, tolerability, PK, and PD of budoprutug in adult participants with SLE.

In Phase 1b, participants who fulfill the 2012 Systemic Lupus International Collaborating Clinics(SLICC) classification criteria for SLE, and who have active SLE (as defined by a SLEDAI ≥ 4 at Screening and Day 1),have failed at least 1 line of treatment, and who are assessed as appropriate for the study by the Eligibility Adjudicator, will be enrolled in sequential escalating dose cohorts. Three dose cohorts are planned.

The Phase 2a expansion cohort will include approximately 16 to 20 participants with active SLE, at least one-half of whom will have renal involvement. Participants will continue to be followed through Week 52 for safety, PK, and PD assessmentsParticipants will also be monitored during this time for ongoing clinical response, safety parameters, and kinetics of re-population of B-cell subsets after the return of B cells to baseline values.

02

Conditions studied

  • Systemic Lupus Erythematosus
  • SLE
  • B Cells
03

In context

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Tenet Medicines is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:.

  • Diagnosis of SLE fulfilling SLICC criteria or 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria at least 24 weeks prior to study entry, with one of the following at Screening
  • If taking a regimen prior to Screening, currently receiving ≤ 20 mg prednisone or equivalent by Day -28. Exceptions for patients with active LN are detailed in Section XX (where we talk about CS use).
  • Female participants of non- must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or , defined as spontaneous amenorrhea for at least 1 year, with follicle-stimulating hormone in the postmenopausal range at Screening, as per central laboratory reference range.

Additional criteria for Phase 2a participants only:

  • Hybrid SLEDAI ≥ 6 at Screening AND Day 1. Note: only the clinical aspects of hybrid SLEDAI must be confirmed on Day 1; laboratory values that contribute to hybrid SLEDAI do not need to be re-measured prior to dosing on Day 1. Additional criteria for contributions to hybrid SLEDAI are as follows:
  • Participants with neurological system contribution to hybrid SLEDAI will not be enrolled.
  • At least 6 points from the hybrid SLEDAI score must be derived from organ system involvement excluding points from oral ulcers, alopecia, or anti-dsDNA auto-antibododies

Additional criteria for Phase 2a participants with LN:

  • Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV LN as evidenced by renal performed within 2 years prior to or during Screening, either with or without the presence of Class V LN.
  • Proteinuria (UPCR > 1.0 gram per gram [g/g]), based on a sample from a 24 hour urine collection during Screening.
  • Estimated (eGFR) ≥ 30 mL/min/1.73 m2 (as calculated by the Chronic Kidney Disease Epidemiology Collaboration formula).
  • Currently receiving 1 or more agents that has been stable for dose and route of administration for ≥ 8 weeks prior to baseline.

Exclusion Criteria:

  • Use of IV, intramuscular, intra-articular, or high-potency intralesional corticosteroids within 6 weeks prior to Screening or expectation of requiring parenteral corticosteroids during the study. Exceptions include protocol required pre-medication prior to infusion of budoprutug.
  • Use of high-potency topical corticosteroid and/or topical agents (immunosuppressant) for skin lesions within 7 days prior to Screening
  • The following laboratory values:

    • \< 1.0 × 109/L.
    • White blood cell count \< 2.0 × 109/L.
    • Cluster of differentiation (CD) 19 B-cell count \<80 cells/µL.
    • (AST) and/or alanine aminotransferase (ALT) > 2 × .
    • Total > 1.5 × ULN, unless due to Gilbert's syndrome.
  • History of serious or significant infusion reaction associated with rituximab, belimumab, anifrolumab, or other monoclonal antibody therapy.
  • History of or current diagnosis of active tuberculosis, untreated latent tuberculosis infection (LTBI) or undergoing current treatment for untreated LTBI
  • History of chronic (i.e., chronic urinary tract infection), recurrent (3 or more of the same type of infection in a 52-week period), latent, or recent serious infection
  • Any previous use of CD19 targeted therapy (e.g., inebilizumab or cell therapy).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Dose 1

    Low dose

    Drug: budoprutug

  • Experimental
    Dose 2

    Middle dose

    Drug: budoprutug

  • Experimental
    Dose 3

    High Dose

    Drug: budoprutug

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

    Safety assessments of budoprutug include changes in vital signs, clinical findings on physicial exam, electrocardiogram and clinical laboratory findings

    Time frame: Day 1 through Week 24

Secondary outcomes

  1. PK parameters

    Area under the maximum observed concentration (AUC)

    Time frame: Day 1 through Week 24

  2. PK parameters

    Peak concentration (Cmax)

    Time frame: Day 1 through Week 24

  3. PK parameters

    Time to maximum observed concentration(T-max)

    Time frame: Day 1 through Week 24

  4. PK parameters

    Terminal half-life

    Time frame: Day 1 through Week 24

  5. PK parameters

    Apparent clearance

    Time frame: Day 1 through Week 24

  6. PK parameters

    Volume of distribution

    Time frame: Day 1 through Week 24

  7. Immunogenicity

    Incidence of anti-drug antibodies (ADA)

    Time frame: Day 1 through Week 24

  8. Immunogenicity

    Time-course of anti-drug antibodies (ADA)

    Time frame: Day 1 through Week 24

  9. Immunogenicity

    Titers of anti-drug antibodies (ADA)

    Time frame: Day 1 through Week 24

Other outcomes

  1. Exploratory

    Change in urine protein creatinine ratio measured in g/g

    Time frame: Day 1 through Week 24

  2. Exploratory

    Changes in b cell subsets measured in µL

    Time frame: Day 1 through Week 24

  3. Exploratory

    Change over time in Physician's Global Assessment of Disease Activity

    Time frame: Day 1 through Week 24

  4. Exploratory

    Change in Systemic Lupus Erythematosus Disease Activity Index

    Time frame: Day 1 through Week 24

  5. Exploratory

    Change in Functional Assessment of Chronic Illness Therapy

    Time frame: Day 1 through Week 24

  6. Exploratory

    Change in Participant's Global Assessment of Disease Activity

    Time frame: Day 1 through Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 26, 2024
StartEst.
Jan 2025
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570434
Lead sponsor
Tenet Medicines
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Jan 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 16, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budoprutug

Start the discussion